Non-Viral Drug Delivery Systems Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Non-Viral Drug Delivery Systems Market Size Changed, over the years?
The market size of non-viral drug delivery systems has witnessed a rapid expansion in the past few years. There is an anticipation of its growth from $8.6 billion in 2024 to $9.84 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.4%. Factors that have contributed to the historical growth of this market encompass the escalating demand for more secure gene therapies, the progressive advancements in the field of nanotechnology, an upsurge in the instances of chronic illnesses, a growing interest in personalized medication, and an increase in regulatory backing for non-viral mechanisms.
How Much Will the Non-Viral Drug Delivery Systems Market Be Worth in 2029?
Expectations are high for the non-viral drug delivery systems market to experience fast expansion in the upcoming years. It’s predicted to escalate to a value of $16.72 billion by 2029, showcasing a compound annual growth rate (CAGR) of 14.2%. Multiple factors fueling growth during this projected period include the rising preference for targeted therapies, continuous investments in drug delivery research, increased favorability towards non-invasive treatments, the growing amalgamation of artificial intelligence and a surge in demand for sustained-release formulations. Noteworthy trends expected to define this period encompass the progress in nanocarrier technology, enhancement in biomaterials for superior delivery, evolution in mRNA delivery platforms, the adoption of smart drug delivery devices, and improvements in gene editing delivery methods.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
Which is the Largest Company in the Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
What Are the Main Market Drivers in the Non-Viral Drug Delivery Systems Industry?
The surge in the need for tailored medications is set to stimulate expansion in the non-viral drug delivery systems market. Customized medical treatment, informed by a person’s genetics, lifestyle, and environment is what characterizes personalized medicine. Its popularity is growing due to its effectiveness in addressing the unique disease triggers in each individual. Non-viral systems are instrumental in this field as they facilitate safe drug or gene transport to cells, minimize risks, and enhance treatment accuracy. For example, the Personalized Medicine Coalition, a non-profit entity based in the United States, reported that in 2023, the FDA greenlit 16 new customized treatments for patients with rare ailments, a significant rise from the six approvals in 2022. Hence, the escalating need for tailored medications is catalyzing the non-viral drug delivery systems market’s progression.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp
How Is the Non-Viral Drug Delivery Systems Market Segments Structured?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
What Strategic Trends Are Transforming the Non-Viral Drug Delivery Systems Market?
Leading firms in the non-viral drug delivery system market are honing in on advanced innovations like pre-optimized ionizable lipid mix systems, which improve the creation and distribution of RNA-based therapies. This particular methodology allows efficient encapsulation of RNA molecules into lipid nanoparticles, which guarantees robust stability, payload safety, and targeted delivery for gene-based drug application scenarios. In context, Cytiva, a biotech firm based in the US, rolled out an RNA delivery LNP tool in September 2024. This tool is matched with its NanoAssemblr Ignite and Ignite+ platforms and features a ready-made ionizable lipid mix that accelerates the screening process of RNA payloads and certifies their effective delivery, primarily in relation to the advancement of infectious disease vaccines. The system synchronizes well with automated microfluidic platforms, supports expansion of production via GMP-grade elements, and comes with guidelines and concept evidence data to steer users from initial discovery through to clinical assessment.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24628
This Report Delivers Insight On:
1. How big is the non-viral drug delivery systems market, and how is it changing globally?
2. Who are the major companies in the non-viral drug delivery systems market, and how are they performing?
3. What are the key opportunities and risks in the non-viral drug delivery systems market right now?
4. Which products or customer segments are growing the most in the non-viral drug delivery systems market?
5. What factors are helping or slowing down the growth of the non-viral drug delivery systems market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
